4 results
The aim of this study is to investigate what proportion of HBeAg negative, inactive carriers of the hepatitis B virus with low (< 20,000 IU/mL) load will lose HBsAg when treated with nucleot(s)ide analogue/Peg-IFN combination therapy.
The primary objective of the study is to perform a set of hypothesis-driven analyses on the study data set, aiming to correlate established biomarkers (obtained clinically, from brain MRI, from CSF, from known genetic factors, and from monitoring of…
The primary objective is to develop algorithms that define digital biomarkers for disease progression in Progressive Supranuclear Palsy patients. The biomarkers, when developed systematically, can eventually serve as primary or secondary clinical…
The first objective is to validate novel digital biomarkers for disease progression in de novo Parkinson*s disease patients. The biomarkers can eventually serve as a primary clinical endpoint in additional future clinical studies. As part of this…